Dr Francis is an ophthalmologist clinician-scientist with expertise in ophthalmic genetics and retinal disease. Peter graduated from medical school in the UK and undertook residency in London, UK. He is fellowship trained in retina and genetics (Moorfields Eye Hospital, London, and Casey Eye Institute, USA). Dr Francis has held academic faculty positions at St Thomas’ Hospital, London and most recently, Casey Eye Institute, Portland, USA in which

Sean Ainsworth has fifteen years of experience in pharmaceuticals and biotechnology. His experience includes research at Medical Biology Institute (now Avanir Pharmaceuticals developers of Abreva, the leading cold sore medication) in San Diego, intellectual property at Koyama and Associates in Tokyo, international corporate development consulting at The Mattson Jack Group in St. Louis, MO.

In 2004 Mr. Ainsworth launched Ainsworth BioConsulting

Dr. Steven Bramer has over 26 years of pharmaceutical/biotechnology industrial and academic experience. He has held positions in global companies where he contributed substantially to all stages of development for drugs, biologics, tissues, combination products, and devices. His experience covers a broad range of therapeutic areas, including ophthalmology, and he has dealt extensively with regulatory agencies in the US and abroad. He played an

Managing director of the fund, Nerveda, which invested in RetroSense among many other early stage deals. Cam's background is on biotechnology commercialization. He has held key positions at Dura Pharmaceuticals, CV Therapeutics and Verus Pharmaceuticals.